Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MRG-106
Cobomarsen · 1 trial · 5 indications
| Arm | Type | Description |
|---|---|---|
| Part A, MF | EXPERIMENTAL | Intratumoral Injection of cobomarsen |
| Part B, MF | EXPERIMENTAL | Subcutaneous, intravenous or a combination of systemic and intratumoral administration of cobomarsen with or without stable background therapy |
| Part C, MF | EXPERIMENTAL | Subcutaneous or intravenous administration of cobomarsen as monotherapy |
| Part D, CLL | EXPERIMENTAL | Subcutaneous or intravenous administration of cobomarsen as monotherapy |
| Part E, DLBCL, activated B-cell (ABC) subtype | EXPERIMENTAL | Subcutaneous or intravenous administration of cobomarsen as monotherapy |
| Part F, ATLL | EXPERIMENTAL | Subcutaneous or intravenous administration of cobomarsen as monotherapy |
| Name | Type | Description |
|---|---|---|
| Cobomarsen | DRUG | - |
Inclusion Criteria: * Parts A-C only: Patients must have biopsy proven MF, clinical stage I, II, or III (excluding visceral or nodal involvement), and must be refractory to or intolerant of established therapies for their condition * Part D only: Patients diagnosed with CLL who are intolerant to, o...
Top 1 of 2 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Incyte Corporation | INCY | 2 | PHASE2 | Ruxolitinib |
Cobomarsen is being developed for the treatment of cutaneous T-cell lymphoma (CTCL), including mycosis fungoides. It has also been studied in chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and adult T-cell leukemia/lymphoma. It is an investigational RNA therapy and is not approved for commercial use.
Cobomarsen is an antisense oligonucleotide, an RNA therapy designed to target RNA rather than protein. Antisense oligonucleotides bind complementary RNA sequences to modulate gene expression. The specific molecular target of cobomarsen is not stated here, so its precise mechanism of action cannot be described beyond its antisense oligonucleotide class.
Cobomarsen is being developed by CASI Pharmaceuticals, Inc., which trades under the ticker CASI. The company holds the development program for this investigational antisense oligonucleotide therapy in oncology indications including cutaneous T-cell lymphoma.
Cobomarsen is in Phase 1 clinical development. It is an investigational therapy and has not been approved by the FDA. The Phase 1 program has completed, with one completed trial and no active trials currently listed.
Cobomarsen has been evaluated in one clinical trial, NCT02580552, titled a study of safety, tolerability and pharmacokinetics of MRG-106 in patients with mycosis fungoides, CLL, DLBCL or ATLL. That Phase 1 trial is completed, enrolled 66 patients, and was conducted in the United States.
Yes, Cobomarsen is also known as MRG-106. The Phase 1 trial NCT02580552 was conducted under the MRG-106 name in patients with mycosis fungoides, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and adult T-cell leukemia/lymphoma. Both names refer to the same investigational antisense oligonucleotide developed by CASI Pharmaceuticals.